Class action lawsuit filed regarding Aardvark Therapeutics, Inc. stock
AARD Aardvark Therapeutics Inc
$5.04 -3.45%
View chart & analysis → - 1Robbins LLP announced that a class action lawsuit has been filed on behalf of investors who purchased Aardvark Therapeutics, Inc. stock between February 13, 2025, and May 14, 2026.
- 2Aardvark Therapeutics, Inc. voluntarily discontinued the Phase 3 HERO clinical trial on February 27, 2026.
- 3The U.S. Food and Drug Administration issued a full clinical hold on the ARD-101 investigational new drug application on May 14, 2026.
So what's the key point?
A lawsuit has begun targeting people who bought stock after the drug trials being conducted by Aardvark Therapeutics, Inc. were stopped. This follows a decision by the U.S. Food and Drug Administration to order a halt to the clinical trials for the company's new drug application.
Source Newsfile · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.